All AbMole products are for research use only, cannot be used for human consumption.
In the cisplatin-resistant HNSCC cell lines Cal27 CisR and Kyse510, LMK-235 enhanced markedly the cytotoxicity of cisplatin.A comparison of the IC50 values of the four most potent compounds with those obtained for HepG2 cells (Table 2) indicates that LMK-235 is cytotoxic.
Life Sci. 2023 Dec 1;1:334:122173.
Applying HDACis to increase SSTR2 expression and radiolabeled DOTA-TATE uptake: From cells to mice
LMK-235 purchased from AbMole
Cancers (Basel). 2021 Sep 29;13(19):4905.
Comparing the Effect of Multiple Histone Deacetylase Inhibitors on SSTR2 Expression and [111In]In-DOTATATE Uptake in NET Cells
LMK-235 purchased from AbMole
 |
Source | Cell Death Differ (2017). Figure 1. LMK-235 |
| Method | Cell viability | |
| Cell Lines | Human third molars | |
| Concentrations | 50 and 100 nM | |
| Incubation Time | 3 days | |
| Results | In addition, the proliferation of the 1,000 nM group was reduced at days 1, 5 and 7 compared with the 0 nM group. However, low concentrations of LMK-235 (50 and 100 nM) barely affected the proliferation of DPCs |
| Molecular Weight | 294.35 |
| Formula | C15H22N2O4 |
| CAS Number | 1418033-25-6 |
| Solubility (25°C) | DMSO 27 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related HDAC Products |
|---|
| CM-444
CM-444 is an inhibitor for HDAC and DNA methyltransferases (DNMT) with IC50 values of 6 nM-0.6 μM and 1.8-2.3 μM, respectively. CM-444 is an inducer for the differentiation of acute myeloid leukemia cells. CM-444 exhibits anti-leukemic activity and improves the survival rate in mouse models. |
| CM-1758
CM-1758 is a histone deacetylase (HDAC) inhibitor. CM-1758 inhibits tumor growth in vivo. CM-1758 induces acetylation of non-histone proteins in acute myeloid leukemia cells. |
| T-518
T-518 is an orally active, selective, and blood-brain barrier permeable HDAC6 inhibitor with an IC50 value of 36 nM for human HDAC6. |
| SE-7552
SE-7552, a 2-(difluoromethyl)-1,3,4-oxadiazole (DFMO) derivative, is an orally active, highly selective, non-hydroxamate HDAC6 inhibitor with an IC50 of 33 nM. |
| BRD9757
BRD9757 is a potent, capless and selective HDAC6 inhibitor with an IC50 of 30 nM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
